Condition
Advanced Ovarian Cancer clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Advanced Ovarian Cancer clinical trials that are recruiting, at sites in 6 countries (most in United States (2), United Kingdom (1), Italy (1)). By phase: Phase 1 (2), Phase 2 (1), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 6Countries
Newest Advanced Ovarian Cancer clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Centralization of Epithelial Ovarian Cancer Care and Outcomes in Italy | — | Carpi, Modena and 6 other locations | Recruiting | Jul 20, 2025 |
| BMS-986500 alone or with other therapies for advanced solid tumors | Phase 1 | Birmingham, Alabama and 20 other locations | Recruiting | May 30, 2025 |
| MOv18 IgE treatment for platinum-resistant ovarian cancer | Phase 1 | Bristol and 6 other locations | Recruiting | Aug 9, 2024 |
| Neoadjuvant AK104 with chemotherapy before surgery in advanced ovarian cancer | Phase 3 | Hefei, Anhui | Recruiting | Aug 7, 2024 |
| 2X-121 treatment for recurrent advanced ovarian cancer | Phase 2 | Oklahoma City, Oklahoma and 1 other locations | Recruiting | Mar 18, 2019 |
All recruiting trials (5)
-
Centralization of Epithelial Ovarian Cancer Care and Outcomes in Italy
This study tests how concentrating ovarian cancer treatment in high-volume centers during 2018–2023 affected patient outcomes.
-
BMS-986500 alone or with other therapies for advanced solid tumors
This trial will test whether BMS-986500 by itself or combined with palbociclib and fulvestrant can help adults with advanced solid tumors, including breast and ovarian cancers, especially after CDK4/6 inhibitor treatment.
-
MOv18 IgE treatment for platinum-resistant ovarian cancer
This study is testing a new treatment called MOv18 IgE for people with platinum-resistant ovarian cancer to see if it can help shrink tumors and improve their health.
-
Neoadjuvant AK104 with chemotherapy before surgery in advanced ovarian cancer
This study tests a combination of AK104 with chemotherapy before surgery to see if it helps patients with advanced ovarian cancer who are at high surgical risk.
-
2X-121 treatment for recurrent advanced ovarian cancer
This study will test whether two dose schedules of the experimental drug 2X-121 (600 mg or 800 mg daily, split twice daily) are safe and effective for people with recurrent advanced ovarian cancer that is platinum‑resistant or platinum‑ineligible.
Related topics
Quick answers
How many Advanced Ovarian Cancer clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 6 countries. The most sites are in United States (2 trials), United Kingdom (1 trial), Italy (1 trial), Denmark (1 trial), Japan (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 2, Phase 2: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.